Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Acerus Pharmaceuticals Corporation (T:ASP)

Business Focus: Pharmaceuticals

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for ASP within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jun 23, 2020 19:00 ET
Acerus Announces Voting Results for the 2020 Annual Meeting
Acerus Pharmaceuticals Corporation (“Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced the voting results from its annual meeting of shareholders held on June 23, 2020 in Toronto, Ontario. The total number of shares represented in person or by proxy at the meeting was 898,135,427, representing 88.88% of the total issued and outstanding Acerus shares.
Read full article
Jun 18, 2020 17:30 ET
Acerus Commences Litigation in the U.K. Against Recipharm Over Estrace® Manufacturing Disruption
Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPF) today announced that it has commenced litigation against Recipharm Limited (“Recipharm”), a wholly-owned subsidiary of Recipharm AB (RECI-B.ST), in the Commercial Court of London. Acerus alleges that the suspension of Recipharm’s manufacturing license in August 2018, in contravention of its contractual obligations to Acerus, led to a shortage of Estrace® in Canada. In 2018, Estrace® generated sales revenues of USD$4.2M. However, due to the shortage, Estrace® revenues and Aceru
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.51
--
--
Price to Sales - TTM
23.47
4.90
8.64
Price to Book - most recent quarter
3.34
2.30
2.51
Price to Cash Flow per share - TTM
--
8.97
11.85
Price to Free Cash Flow per share - TTM
--
12.84
22.34
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 30, 2020190,70311,735
Jun 15, 2020178,96814,118
May 31, 2020164,850-43,018
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Acerus Pharmaceuticals Corporation, formerly Trimel Pharmaceuticals Corporation, is a Canada-based pharmaceutical company. The Company is engaged in the development, manufacture, marketing and distribution of products with a focus on men's health, including urology, and women's health, including hormone replacement therapy and female sexual dysfunction. The Company markets Estrace in Canada, which is an oral, plant-derived 17-beta estradiol therapy for the relief of symptoms of menopause. The Company offers Natesto, which is the testosterone nasal gel in the United States for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). The Company offers TEFINA, which is a low-dose nasal testosterone gel treatment in development for female sexual dysfunction. The Company focuses on TriVair Deposition/Dispersion System, which is a unit dose dry powder inhaler and nasal dispersion system.

See business summary

 

Twitter

Search (past week) for $ASP.CA

  • No tweets found